TYK37: Difference between revisions
m 1 revision imported |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
Which of the following neuromuscular blocking agents (NMBA) has a clinically significant metabolite in patients with renal failure? | Which of the following neuromuscular blocking agents (NMBA) has a clinically significant metabolite in patients with renal failure? | ||
| Line 10: | Line 9: | ||
D. Mivacurium | D. Mivacurium | ||
<div class="mw-customtoggle-TYK_Answer" style="text-align: right; color:#0000ff">Click for Answer</div> | |||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-TYK_Answer"> | |||
<div class="mw-collapsible- | |||
==Answer== | ==Answer== | ||
The answer is A. Vecuronium undergoes 30-40 metabolism in the LIVER. Its elimination is mixed (40-50% by the kidney and 50-60% by the liver). However, the extensive metabolism in the liver produces a 3-OH metabolite. This metabolite will accumulate in renal failure and is active with an 80% potency of vecuronium. Rocuronium has no metabolism or active metabolites. Its is eliminated by the kidney (10-25%) and the liver (70%). Cisatracurium undergoes Hoffman elimination (77%) with some kidney elimination (16%). Mivacurium is metabolized by butyrylcholinesterase (95-98%) with minor renal elimination (<5%). Mivacurium and cistracurium have some metabolites, but these are not known to have any significant clinical effect. | The answer is A. Vecuronium undergoes 30-40 metabolism in the LIVER. Its elimination is mixed (40-50% by the kidney and 50-60% by the liver). However, the extensive metabolism in the liver produces a 3-OH metabolite. This metabolite will accumulate in renal failure and is active with an 80% potency of vecuronium. Rocuronium has no metabolism or active metabolites. Its is eliminated by the kidney (10-25%) and the liver (70%). Cisatracurium undergoes Hoffman elimination (77%) with some kidney elimination (16%). Mivacurium is metabolized by butyrylcholinesterase (95-98%) with minor renal elimination (<5%). Mivacurium and cistracurium have some metabolites, but these are not known to have any significant clinical effect. | ||
==Notes== | ==Notes== | ||
<references /> | <references /> | ||
==Keywords== | ==Keywords== | ||
</div> | </div> | ||
---- | ---- | ||
---- | ---- | ||
| Line 32: | Line 24: | ||
<p style="text-align: center;">[[TYK36|<Prev Question]] --- [[TYK38|Next Question>]]</p> | <p style="text-align: center;">[[TYK36|<Prev Question]] --- [[TYK38|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:38, 25 September 2026
Which of the following neuromuscular blocking agents (NMBA) has a clinically significant metabolite in patients with renal failure?
A. Vecuronium
B. Rocuronium
C. Cisatracurium
D. Mivacurium
Answer
The answer is A. Vecuronium undergoes 30-40 metabolism in the LIVER. Its elimination is mixed (40-50% by the kidney and 50-60% by the liver). However, the extensive metabolism in the liver produces a 3-OH metabolite. This metabolite will accumulate in renal failure and is active with an 80% potency of vecuronium. Rocuronium has no metabolism or active metabolites. Its is eliminated by the kidney (10-25%) and the liver (70%). Cisatracurium undergoes Hoffman elimination (77%) with some kidney elimination (16%). Mivacurium is metabolized by butyrylcholinesterase (95-98%) with minor renal elimination (<5%). Mivacurium and cistracurium have some metabolites, but these are not known to have any significant clinical effect.
Notes